Degradation of CHK2 has been linked to cisplatin-induced resistance in ovarian cancer cells (Zhang et al, 2005), and alterations in the CHK2 pathway predict poor prognosis in ovarian cancer (Hashiguchi et al, 2004). Here, CHEK2 is linked to ovarian carcinoma.